Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NCI/CMS Group Will Examine Coverage For Off-Label Cancer Drug Use

This article was originally published in The Pink Sheet Daily

Executive Summary

The collaboration between the National Cancer Institute and Centers for Medicare & Medicaid Services will work to formulate a policy that may be useful for commercial health insurance coverage of drugs, an NCI rep says.

You may also be interested in...



Antimicrobial Drug Development Could Benefit From Smaller Clinical Trials, FDA Says

Studies of drugs for resistant pathogens could apply data from susceptible pathogens, CDER’s Powers tells Antimicrobial Resistance Interagency Task Force meeting. The agency plans to issue several antimicrobial-related guidances this summer.

Antimicrobial Drug Development Could Benefit From Smaller Clinical Trials, FDA Says

Studies of drugs for resistant pathogens could apply data from susceptible pathogens, CDER’s Powers tells Antimicrobial Resistance Interagency Task Force meeting. The agency plans to issue several antimicrobial-related guidances this summer.

CMS/NCI Collaboration Will Encompass Post-Approval Studies

Memorandum of understanding will create a mechanism to identify “high-priority clinical questions.” The collaboration also will examine off-label coverage of cancer drugs and reimbursement for new technologies.

Related Content

Topics

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel